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496Background: We evaluated the safety and feasibility of minimally invasive mitral valve repair with papillary
muscle sling placement via a right anterior thoracotomy approach in patients with severe functional mitral
regurgitation (MR).
Methods: We retrospectively reviewed all minimally invasive mitral valve repairs with papillary muscle sling
placement in patients with severe functional MR performed at our institution between October 2011 and Sep-
tember 2012. The operative times, lengths of stay, postoperative complications, and mortality were analyzed.
Results: We identified a total of 19 consecutive patients. There were 12 men (63%); the mean age was 60 13
years. Themean SD left ventricular ejection fraction was 23% 5.5%, and 4 (21%) of the patients underwent
previous coronary artery bypass graft surgery. The median aortic cross-clamp and cardiopulmonary bypass times
were 106 (interquartile range [IQR], 76-120) and 163 (IQR, 119-170)minutes, respectively. Themedian intensive
care unit length of staywas 64 (IQR, 43-75) hours, and themedian postoperative length of staywas 7 (IQR, 5-7.5)
days. Postoperatively, 2 patients developed acute kidney injury. There were no reoperations for bleeding or any
cerebrovascular accidents. The 30-day mortality was 0. A follow-up echocardiogram, obtained at a median of
3 (IQR, 1-7.5) months, demonstrated none to trivial MR in all patients.
Conclusions:Minimally invasive mitral repair with papillary muscle sling placement for severe functional MR
is safe and effective in the short-term. Long-term data are needed to evaluate the effects on left ventricular
remodeling and to assess the durability of the repair. (J Thorac Cardiovasc Surg 2014;147:496-9)In patientswith left ventricular systolic dysfunction and func-
tional mitral regurgitation (MR), the surgical treatment of the
mitral insufficiency is a challenging issue. Most of these
individuals have a structurally normal mitral valve, but the
valve is incompetent because left ventricular remodeling
has disturbed the relationship between the subvalvular appa-
ratus and the mitral valve leaflets. Therefore, more attention
is given to correcting the papillary muscle displacement
when these individuals undergo mitral valve repair. One of
these approaches involves the placement of a sling around
the papillarymuscles. This technique has been previously re-
ported as being performed via median sternotomy.We report
our experience performing this technique using a minimally
invasive approach via a right lateral thoracotomy.
METHODS
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The Journal of Thoracic and Cardiovascular Surgretrospectively reviewed all heart operations performed at our institution
between November 2011 and September 2012, to identify patients with
functional MR who underwent mitral valve repair with papillary muscle
sling placement using a minimally invasive approach.
All patients had their valvular lesions documented by diagnostic cathe-
terization and echocardiography, and all operative reports and echocardio-
grams were reviewed. Intraoperative transesophageal echocardiography
was performed to evaluate the mitral valve, and grading of the MR was
done in accordancewith the American Society of Echocardiography guide-
lines.1 The MR was graded as severe (4þ), moderate to severe (3þ), mod-
erate (2þ), mild (1þ), or trace/none (0). A postoperative transesophageal
echocardiogramwas obtained to evaluate the repair. The surgical technique
time was analyzed on the basis of aortic cross-clamp and total cardiopul-
monary bypass times. The outcome variables evaluated were 30-day mor-
tality and postoperative complications, which were identified as follows:
postoperative renal failure, bleeding requiring reoperation, cerebrovascular
accident, prolonged ventilation (>24 hours), reintubation, deep wound in-
fection, and atrial fibrillation. The definitions and variables selected were
based on the Society of Thoracic Surgeons Database definitions. All
patients were evaluated approximately 30 days postoperatively in the out-
patient setting.
Surgical Technique
A femoral platform was used to establish cardiopulmonary bypass. A
longitudinal 2- to 3-cm incision was made superior to the inguinal crease.
The femoral artery was cannulated with a 16F to 18F arterial cannula
(Edwards, Irvine, Calif) or a 15F to 19F arterial cannula (Bio-medicus;
Medtronic, Minneapolis, Minn), and the femoral vein was cannulated
with a 25F venous cannula (Bio-medicus, Medtronic). With the aid of
transesophageal echocardiography, the venous cannula was placed in the
superior vena cava. A 5- to 6-cm skin incision was made in the right fourth
to fifth intercostal space lateral to the anterior axillary line. A soft tissue
retractor and rib spreader were used to provide further exposure. Theery c January 2014
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IQR ¼ interquartile range
MR ¼ mitral regurgitation
Santana et al Evolving Technology/Basic Science
E
T
/B
Spericardium was opened over the phrenic nerve and tacked to the skin. By
using transesophageal echocardiographic guidance, a retrograde coronary
sinus catheter was inserted into the right atrium directly through the inci-
sion. One dose of antegrade cold blood cardioplegia was given to establish
electromechanical arrest of the heart. Thereafter, retrograde cold blood car-
dioplegia was given throughout the procedure at 20-minute intervals. A left
lateral atriotomy is performed through theWaterson groove to enter the left
atrium. An atrial lift retractor and atrial exposure blade were used for visu-
alization of the mitral valve. A specially designed papillary exposure
device was used to visualize the infravalvular apparatus. We do not place
the mitral annular sutures first because this impairs visualization. A long-
shafted curved clamp was used to encircle all sets of papillary muscles.
This procedure needs to be performed carefully to not penetrate the papil-
lary muscles. In addition, the clamp needs to be as close to the base of the
papillary muscles as possible. Different size clamps are required depending
on the width of the muscles. This maneuver can be time-consuming for it to
be performed properly. This will avoid the graft slipping superiorly and en-
trapping the chordae. A 4-mm polytetrafluoroethylene graft (Gore-Tex;
W. L. Gore & Associates, Inc, Newark, Del) was then placed around the
base of the papillary muscles (Figure 1). Care is taken to place the graft
so that it has an anchoring muscle that will prevent upward migration.
The edges of the sling are approximated as tightly as possible and tied
with a 4-0 Prolene suture (Ethicon, Inc, Somerville, NJ) in a mattress man-
ner and then a continuous over-and-over manner. This may require several
sutures to apply the maximum tension to approximate the graft. At the
completion, the papillarymuscles are tightly approximated and juxtaposed.
Thereafter, the mitral valve repair was performed. The size of the anterior
leaflet was used to determine the size of the annuloplasty ring. We do not
undersize the ring. The annuloplasty ring used was a profile three-
dimensional ring (Medtronic). A 4-0 Prolene suture was used to close the
left atrium. Carbon dioxide was infused into the operative field at 2 L/min
throughout the entire procedure.
When concomitant tricuspid valve surgery was performed, the superior
and inferior vena cavae were encircled with vessel loops. Before the right
atrium was opened, the long femoral venous cannula was withdrawn into
the inferior vena cava and then both cavae were snared with the vessel
loops. The right atrium was then opened, and a sump suction was inserted
into the superior vena cava to provide drainage. We did not use a separate
venous cannula.
In patients with a history of coronary artery bypass surgery, moderate to
deep hypothermia (24C-26C) and fibrillatory arrest were used. Cardio-
plegia was not delivered at all. Removal of air was performed via a vent
placed through the atriotomy into the left ventricle and an aortic root vent.
In patients with a history of atrial arrhythmias, a concomitant modified
left atrial ablation procedure was performed first after exposure of the left
atrium and mitral valve. The intra-atrial ablation lines were created with
a saline irrigated unipolar radiofrequency probe (Cardioblate; Medtronic).
The ablation lines included isolation of the pulmonary veins, followed by
a box lesion communicating the pulmonary veins. Additional lines were
created around the left atrial appendage, and from the appendage to the
left pulmonary veins. The last lesion set was from the left pulmonary veins
to the mitral annulus (P2-P3 region). The left atrial appendage was ligated
from within the left atrium with a double row, continuous suture line. We
did not perform right atrial ablation in any of the patients.
With the heart empty, a ventricular pacing wire was placed. After dis-
continuing cardiopulmonary bypass and administering protamine, decan-
nulation was performed. The purse string sutures were tied, and theThe Journal of Thoracic and Cafemoral artery was reinforced using a 5-0 Prolene suture. A single chest
tube was left in the pleural space. For pain relief, an On-Q pain relief sys-
tem was inserted (I-Flow Corporation, Lake Forest, Calif). Two catheters
were placed to continuously deliver 0.25% bupivacaine for 72 hours.
The thoracotomy incision was closed in the routine manner.
Statistical Methods
Continuous variables are expressed as the mean SD or median and in-
terquartile range (IQR, 25th-75th quartile), as appropriate. The statistical
analyses were performed using SPSS, version 17 (SPSS Inc, Chicago, Ill).
RESULTS
We identified 19 consecutive patients, consisting of 12
(63%) men and 7 (37%) women, with a mean age of
60  13 years. The mean ejection fraction was
23%  5.5%, with a mean mitral valve tenting height of
10  2 mm. There were 4 (21%) patients with a history
of coronary artery bypass graft surgery. In all patients, the
MR was functional, with an ischemic cause in 9 (47%)
and a nonischemic origin in 10 (53%). All patients were
in New York Heart Association Functional class III to IV
(Table 1). Of the 19 patients, 2 underwent concomitant
tricuspid valve repair due to the presence of moderate to se-
vere tricuspid regurgitation and 3 underwent a concomitant
ablation procedure for atrial fibrillation.
The median aortic cross-clamp and cardiopulmonary by-
pass times were 106 (IQR, 76-120) and 163 (IQR, 119-170)
minutes, respectively. On postoperative transesophageal
echocardiogram, none of the patients had any discernible
MR. The median number of units of packed red blood cells
transfused was 1 (IQR, 0-2). The median intensive care unit
length of stay was 64 (IQR, 43-75) hours. Postoperatively, 2
(10.5%) patients developed renal failure. None of the pa-
tients had a cerebrovascular accident, required reoperation
for bleeding, or developed a deep wound infection. The me-
dian postoperative length of stay was 7 (IQR, 5-7.5) days
(Table 2). There were no operative deaths, and at a median
follow-up of 9.5 (IQR, 6.5-12) months, all patients were
alive.
A follow-up echocardiogram, obtained at a median of 3
(IQR, 1-7.5) months, demonstrated none to trivial MR in
all patients. The mean ejection fraction increased to
31%  17%, and the mitral valve tenting height was
reduced to a mean of 5  2 mm.
DISCUSSION
Functional, or secondary, mitral insufficiency in patients
with reduced left ventricular systolic function is usually
a result of annular dilatation and papillary muscle displace-
ment, with the mitral leaflets being anatomically normal.2
Whether to perform mitral valve surgery in patients with se-
vere MR and advanced heart failure is controversial, with
the published data showing equivocal results.3-5 Thus, to
our knowledge, the optimal approach to the management
of individual patients with functional MR has not beenrdiovascular Surgery c Volume 147, Number 1 497
TABLE 2. Operative results and postoperative outcomes
Variables Value (N ¼ 19)
Aortic cross-clamp time, min 106 (76-120)
Cardiopulmonary bypass time, min 163 (119-170)
PRBCs transfused, U 1 (0-2)
Intra-aortic balloon pump use* 2 (11)
Total ventilator time, h 16 (10.5-22)
Intensive care unit length of stay, h 64 (43-75)
Renal failure* 2 (10.5)
Prolonged intubation* 4 (21)
Atrial fibrillation* 1 (5)
Hospital length of stay, d 7 (5-7.5)
Values are given as median (interquartile range) unless otherwise indicated. No
patients experienced reoperations for bleeding, cerebrovascular accidents, reintuba-
tions, sternal deep wound infections, or 30-day mortality. PRBC, Packed red blood
cell. *Values are given as number (percentage).
FIGURE 1. Placement of a 4-mm polytetrafluoroethylene (Gore-Tex)
tube around the papillary muscles.
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performed in these cases is an undersized mitral
annuloplasty, which was popularized by Bolling and
colleagues.6 In this technique, a mitral annuloplasty ring
that is downsized by 2 sizes is used to cause a reduction
in the anteroposterior (septolateral) diameter of the mitral
valve, increasing the surface of coaptation. The drawback
with this technique is that it has a high rate of failure,
with reports of up to 28% of patients developing moderate
or more MR within 6 months postrepair.7
To reduce the recurrence of MR in these patients, some
authors have focused their attention on fixing theTABLE 1. Patient baseline characteristics
Variables Value (N ¼ 19)
Age, y* 60  13
Male sex 12 (63)
Hypertension 18 (95)
Diabetes mellitus 6 (32)
Dyslipidemia 14 (74)
Ejection fraction,%* 23  5.5
Previous coronary bypass graft surgery 4 (21)
History of cerebrovascular accident 2 (10.5)
History of atrial fibrillation 7 (37)
Chronic obstructive pulmonary disease 4 (21)
Preoperative creatinine level, mg/dL* 1.0  0.3
Ischemic cardiomyopathy 9 (47)
Nonischemic cardiomyopathy 10 (53)
New York Heart Association functional class III-IV 19 (100)
Values are given as number (percentage) unless otherwise indicated. *Values are
given as mean  SD.
498 The Journal of Thoracic and Cardiovascular Surgsubvalvular apparatus in conjunction with the standard
annuloplasty ring repair. Hvass and colleagues8,9 were the
first to report the use of a 4-mm polytetrafluoroethylene
tube encircling the trabecular base of both papillary
muscles in patients with ischemic functional MR. A
moderately undersized mitral annuloplasty ring was
initially placed in most patients, with the last 10 patients
of the study receiving a normally sized prosthetic mitral
ring. All patients also underwent coronary artery bypass
graft surgery. At 1 year follow-up, there was an improve-
ment in ejection fraction, a reduction in the end-diastolic
and end-systolic diameters, and a reduction in the mean
pulmonary artery systolic pressure.
All of the previously mentioned procedures were done
via a standard median sternotomy.Minimally invasive valve
surgery, when compared with median sternotomy, has been
shown to reduce surgical trauma and decrease morbidity,
especially in high-risk patients, such as elderly and obese
persons.10-14 Therefore, it is tempting to hypothesize that,
by placing a papillary muscle sling during mitral valve
repair via a minimally invasive approach, one may
improve the short- and long-term results of the mitral valve
repairs in these high-risk individuals. Another benefit of us-
ing a minithoracotomy approach is that visualization of the
infravalvular apparatus is improved. At our institution, the
patients we select for this procedure are those with severe
functional MR who have an ejection fraction of 40% or
less. Although the median aortic cross-clamp time was
106 (IQR, 76-120) minutes, this did not seem to have an
adverse effect on outcomes.Study Limitations
The current study is subject to the limitations inherent in
a single-center, retrospective study design. The sample size
is small, and the median follow-up echocardiographic
period is limited, being only 3 months. Therefore, longer-
term data are needed to be able to compare the recurrenceery c January 2014
Santana et al Evolving Technology/Basic Scienceof MR of this approach with the recurrence that has been
noted when undersized mitral annuloplasty is used. Further-
more, all operations were performed by a single surgeon
(J.L.). Thus, our findings can only be cautiously general-
ized. Finally, this study does not address the clinical indica-
tions for mitral surgery in patients with severe left
ventricular dysfunction and functional mitral insufficiency.
CONCLUSIONS
The placement of a papillary muscle sling during mini-
mally invasive mitral valve repair via a right anterior thora-
cotomy for severe functional MR is safe and effective in the
short-term. Long-term data are needed to evaluate the out-
comes of these patients and to assess the durability of the
mitral valve repair.
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